X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs PANACEA BIOTECH - Comparison Results

PROCTER & GAMBLE HEALTH    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH PANACEA BIOTECH PROCTER & GAMBLE HEALTH/
PANACEA BIOTECH
 
P/E (TTM) x 61.0 -5.6 - View Chart
P/BV x 10.7 3.0 355.1% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   PANACEA BIOTECH
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-17
PANACEA BIOTECH
Mar-18
PROCTER & GAMBLE HEALTH/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,358364 372.9%   
Low Rs933129 722.7%   
Sales per share (Unadj.) Rs665.096.8 687.1%  
Earnings per share (Unadj.) Rs56.6-12.4 -455.9%  
Cash flow per share (Unadj.) Rs72.5-2.9 -2,541.0%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs441.750.4 876.5%  
Shares outstanding (eoy) m16.6061.25 27.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.5 67.6%   
Avg P/E ratio x20.2-19.9 -101.9%  
P/CF ratio (eoy) x15.8-86.4 -18.3%  
Price / Book Value ratio x2.64.9 53.0%  
Dividend payout %26.50-   
Avg Mkt Cap Rs m19,01115,101 125.9%   
No. of employees `0001.52.5 62.6%   
Total wages/salary Rs m1,6961,516 111.9%   
Avg. sales/employee Rs Th7,150.02,401.9 297.7%   
Avg. wages/employee Rs Th1,098.7614.2 178.9%   
Avg. net profit/employee Rs Th608.2-307.9 -197.5%   
INCOME DATA
Net Sales Rs m11,0405,928 186.2%  
Other income Rs m24082 291.3%   
Total revenues Rs m11,2796,010 187.7%   
Gross profit Rs m1,376845 162.8%  
Depreciation Rs m264585 45.1%   
Interest Rs m01,006 0.0%   
Profit before tax Rs m1,352-664 -203.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m58399 591.1%   
Profit after tax Rs m939-760 -123.6%  
Gross profit margin %12.514.3 87.4%  
Effective tax rate %43.1-14.9 -290.1%   
Net profit margin %8.5-12.8 -66.4%  
BALANCE SHEET DATA
Current assets Rs m7,5235,603 134.3%   
Current liabilities Rs m2,2536,910 32.6%   
Net working cap to sales %47.7-22.0 -216.6%  
Current ratio x3.30.8 411.9%  
Inventory Days Days52206 25.3%  
Debtors Days Days4184 48.4%  
Net fixed assets Rs m1,2409,941 12.5%   
Share capital Rs m16661 270.8%   
"Free" reserves Rs m7,1673,026 236.9%   
Net worth Rs m7,3333,087 237.5%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m9,91216,076 61.7%  
Interest coverage xNM0.3-  
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x1.10.4 302.0%   
Return on assets %9.51.5 619.6%  
Return on equity %12.8-24.6 -52.0%  
Return on capital %20.83.9 530.0%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m1,0151,600 63.4%   
Fx outflow Rs m3,0431,131 268.9%   
Net fx Rs m-2,028469 -432.8%   
CASH FLOW
From Operations Rs m5371,180 45.5%  
From Investments Rs m-476553 -86.1%  
From Financial Activity Rs m-220-1,644 13.4%  
Net Cashflow Rs m-16090 -177.8%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.6 3,033.3%  
FIIs % 1.0 1.3 76.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.6 123.3%  
Shareholders   28,591 10,259 278.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views on News

PROCTER & GAMBLE HEALTH at All Time High; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Jul 16, 2019 | Updated on Jul 16, 2019

PROCTER & GAMBLE HEALTH share price has hit an all time high at Rs 4,768 (up 9.3%). The BSE HEALTHCARE Index is up by 0.9%. Among the top gainers in the BSE HEALTHCARE Index today are PROCTER & GAMBLE HEALTH (up 9.3%) and SANOFI INDIA (up 0.5%). The top losers include BLISS GVS PHARMA (down 0.2%) and NARAYANA HRUDAYALAYA LTD (down 0.2%).

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jul 16, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - GSK PHARMA COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS